Autonomous disease detection based on retina imaging using artificial intelligence

Aireen is an AI software medical device company focusing on diagnosing chronic diseases from retinal images. The focus is to provide non-invasive, pain-less screening of chronic diseases by analyzing digital images of the retina. 


The retina is the only place in the human body where blood vessels can be seen by the naked eye. Artificial intelligence is cutting-edge breakthrough technology which allows for the precise identification of changes to the retina and their relation with number of chronic diseases.


• Since May 2023 Aireen DR diabetic retinopathy detection has been certified as class IIb EU-MDR medical device.


• In May 2024 age related macular degeneration detection was certified as class IIb EU-MDR medical device.


Our current development activities are aimed at cardiovascular and neurodegenerative disease detection, again from retinal images.


Team Aireen

Jiří Kuchyňa

Jiří Kuchyňa

CEO
David Navrátil

David Navrátil

Founder
Petr Kocian

Petr Kocian

Strategic Partner
Jan Hlaváček

Jan Hlaváček

COO
Martin Slíva

Martin Slíva

CTO
Adam Švrčina

Adam Švrčina

CSO
Renata Ženíšková

Renata Ženíšková

Clinical Researcher
Dana Fillová

Dana Fillová

Clinical Researcher
Jozefína Vaľková

Jozefína Vaľková

Head of Regulatory

Advisory board

prof. MUDr. Jakub Hort, Ph.D.

prof. MUDr. Jakub Hort, Ph.D.

prof. MUDr. Martin Prázný CSc., Ph.D.

prof. MUDr. Martin Prázný CSc., Ph.D.

Doc. MUDr. Martin Šín Ph.D., FEBO

Doc. MUDr. Martin Šín Ph.D., FEBO

Our supporters